Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 2/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696972 | 0.85 | ERN1 (0.50) | ERN1METAP2L3MBTL1ALOX15HTT | |
| SCHEMBL28250987 | 0.81 | ACLY (0.45) | ACLYMETAP2BDKRB1L3MBTL1ALOX15 | |
| SCHEMBL4700610 | 0.79 | L3MBTL1 (0.49) | ACLYMETAP2L3MBTL1ALOX15HTT | |
| SCHEMBL22290184 | 0.79 | SLC6A4 (0.59) | ACLYMETAP2L3MBTL1 | |
| SCHEMBL30499558 | 0.79 | SLC6A4 (0.59) | ACLYMETAP2L3MBTL1 | |
| SCHEMBL9301522 | 0.76 | SLC6A3 (0.57) | ACLYMETAP2L3MBTL1ALOX15HTT | |
| SCHEMBL2561503 | 0.75 | L3MBTL1 (0.57) | ERN1L3MBTL1ALOX15HTTHCRTR1 | |
| SCHEMBL69177 | 0.75 | L3MBTL1 (0.64) | L3MBTL1ALOX15HTT | |
| SCHEMBL698991 | 0.74 | L3MBTL1 (0.55) | ACLYL3MBTL1HTTHCRTR1HCRTR2 | |
| SCHEMBL28865711 | 0.73 | L3MBTL1 (0.51) | ACLYMETAP2BDKRB1L3MBTL1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
| EP-1902022-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007018-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GPR68, GPR55, GPR88 | ERN1 4396/4885ACLY 3564/4885METAP2 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.